10.30
+8.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Contineum Therapeutics
From its filings with the US Securities and Exchange Commission
Contineum Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CTNM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $0.
We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease.
We focus on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical-stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J.
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (“LPA1R”) in development for idiopathic pulmonary fibrosis (“IPF”) and chronic pain. LPA1R antagonism is a clinically validated mechanism in IPF, and we believe that our preclinical studies, Phase 1 healthy volunteer data, and Phase 1 positron emission tomography (“PET”) data support the development of PIPE-791 for IPF and chronic pain. Specifically, based on its high bioavailability, high selectivity, low plasma protein binding, and long receptor residence time, we believe PIPE-791 has the potential to be a differentiated LPA1R therapy. In September 2025, we reported positive top-line data from our completed Phase 1b PET trial which measured the relationship of pharmacokinetics (“PK”) to receptor occupancy (“RO”) by PET imaging.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 5 Apr 2024
- Employees
- 51
- Website
- contineum-tx.com ↗
- Head office
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Evert SchimmelpenninkIndependent Chairman of the Board$482,974
- Mr. Carmine StengonePresident, Chief Executive Officer, Director, since 2018$4.9m
- Mr. Peter SloverChief Financial Officer$1.0m
- Dr. Daniel LorrainChief Science Officer$1.8m
- Mr. John HealyGeneral Counsel, Corporate Secretary$2.6m
- Dr. Timothy WatkinsChief Medical Officer and Head of Development
- Dr. Diego MirallesDirector
- Ms. Sarah BoyceIndependent Director$505,573
- Mr. Todd BradyIndependent Director$831,409
- Mr. Troy IgnelziIndependent Director$424,213
- Ms. Lori Lyons-WilliamsIndependent Director$431,351
- Ms. Olivia WareIndependent Director$484,399
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Contineum Therapeutics Inc focuses on neuroscience, inflammation, and immunology indications with high unmet need.
- Its lead asset PIPE-791 targets idiopathic pulmonary fibrosis and progressive multiple sclerosis.
- The company has three drug candidates including PIPE-791, CTX-343, and PIPE-307.
Weaknesses
- The company has only 31 full-time employees as of the latest data.
- Contineum Therapeutics Inc went public on 5 April 2024 with limited market presence.
- The firm's pipeline includes only three drug candidates at clinical stage.
Opportunities
- The US market offers significant growth potential for biopharmaceutical companies like Contineum.
- The company can expand its pipeline with additional drug candidates for neuroscience and immunology.
- Contineum Therapeutics Inc can leverage its focus on LPA1R antagonism for new indications.
Threats
- The biopharmaceutical industry faces intense competition from established firms.
- Clinical trials for drug candidates may fail or face regulatory hurdles.
- The company's reliance on a limited number of drug candidates poses a risk to its development pipeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.